Associated Genetic Biomarkers
Inositol polyphosphate-4-phosphatase, type II (INPP4B) is a gene that encodes a protein that functions as a dephosphorylating enzyme in the phosphatidylinositol signaling pathways. Missense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and lung cancer.
INPP4B is altered in 1.18% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in INPP4B are INPP4B Mutation (0.75%), INPP4B Amplification (0.09%), INPP4B Loss (0.04%), INPP4B R818Efs*4 (0.02%), and INPP4B R252* (0.01%) .
INPP4B status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains INPP4B status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with INPP4B status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is INPP4B Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with INPP4B as an inclusion criteria .
Significance of INPP4B in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.